Dashboard
Manage Tickers

SRDX SURMODICS INC

Nasdaq surmodics.com


$ 27.48 $ 0.05 (0.16 %)    

Wednesday, 05-Nov-2025 15:59:41 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 27.545
$ 27.70
$ 26.00 x 1
$ 29.00 x 110
$ 25.87 - $ 27.77
$ 25.87 - $ 40.39
115,704
na
393.83M
$ 0.89
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 04-30-2025 03-31-2025 10-Q
3 01-30-2025 12-31-2024 10-Q
4 11-20-2024 09-30-2024 10-K
5 07-31-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-01-2024 12-31-2023 10-Q
8 08-02-2023 06-30-2023 10-Q
9 04-26-2023 03-31-2023 10-Q
10 02-06-2023 12-31-2022 10-Q
11 11-23-2022 09-30-2022 10-K
12 07-27-2022 06-30-2022 10-Q
13 04-27-2022 03-31-2022 10-Q
14 02-04-2022 12-31-2021 10-Q
15 11-24-2021 09-30-2021 10-K
16 08-04-2021 06-30-2021 10-Q
17 04-28-2021 03-31-2021 10-Q
18 02-09-2021 12-31-2020 10-Q
19 12-02-2020 09-30-2020 10-K
20 08-05-2020 06-30-2020 10-Q
21 04-30-2020 03-31-2020 10-Q
22 02-07-2020 12-31-2019 10-Q
23 12-03-2019 09-30-2019 10-K
24 08-01-2019 06-30-2019 10-Q
25 05-03-2019 03-31-2019 10-Q
26 02-01-2019 12-31-2018 10-Q
27 11-30-2018 09-30-2018 10-K
28 08-06-2018 06-30-2018 10-Q
29 05-04-2018 03-31-2018 10-Q
30 02-08-2018 12-31-2017 10-Q
31 12-01-2017 09-30-2017 10-K
32 08-03-2017 06-30-2017 10-Q
33 04-28-2017 03-31-2017 10-Q
34 02-03-2017 12-31-2016 10-Q
35 12-02-2016 09-30-2016 10-K
36 07-29-2016 06-30-2016 10-Q
37 05-10-2016 03-31-2016 10-Q
38 02-05-2016 12-31-2015 10-Q
39 12-04-2015 09-30-2015 10-K
40 08-06-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

surmodics-reports-strong-prowl-registry-results-showing-917-procedural-success-and-06-adverse-events-for-pounce-thrombectomy-in-real-world-limb-ischemia
Surmodics Reports Strong PROWL Registry Re...
11/04/2025 11:17:06

surmodics-doctors-to-share-updated-real-world-results-for-pounce-clot-removal-platform-in-las-vegas
Surmodics Doctors to Share Updated Real-Wo...
11/03/2025 11:20:55

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care ind...

surmodics-prowl-registry-study-data-demonstrates-high-procedural-success-across-sexes-throughout-160-acute-subacute-and-chronic-thrombotic-limb-ischemia-patients
Surmodics Prowl Registry Study Data Demons...
10/29/2025 20:34:55

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care in...

surmodics-to-present-prowl-registry-sex-specific-data-from-analysis-of-160-participants-at-tct-symposium-on-oct-28
Surmodics To Present PROWL Registry Sex-Sp...
10/27/2025 20:11:51

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care in...

barrington-research-reiterates-market-perform-on-surmodicsto-market-perform
Barrington Research Reiterates Market Perf...
08/11/2025 11:52:16

Barrington Research analyst Michael Petusky reiterates Surmodics (NASDAQ:SRDX) from Market Perform to Market Perform.

surmodics-lowers-fy2025-gaap-eps-guidance-from-160-140-to-170-155-vs-147-est
Surmodics Lowers FY2025 GAAP EPS Guidance ...
08/08/2025 11:05:53

surmodics-raises-fy2025-adj-eps-guidance-from-062-042-to-035-020-vs-055-est-raises-fy2025-sales-guidance-from-114000m-117000m-to-116500m-118500m-vs-115686m-est
Surmodics Raises FY2025 Adj EPS Guidance f...
08/08/2025 11:05:37

Fiscal Year 2025 Financial GuidanceSurmodics is increasing its fiscal 2025 total revenue to a range of $116.5 million to $118.5...

surmodics-q3-adj-eps-006-beats-019-estimate-sales-29567m-beat-28055m-estimate
Surmodics Q3 Adj. EPS $0.06 Beats $(0.19) ...
08/08/2025 11:02:44

Core News & Articles
Earnings Scheduled For August 8, 2025
08/08/2025 08:32:13

whats-next-surmodicss-earnings-preview
What's Next: Surmodics's Earnings Preview
08/07/2025 16:03:24

surmodics-reports-unauthorized-it-access-initiates-containment-measures-following-cybersecurity-incident
Surmodics Reports Unauthorized IT Access, ...
07/02/2025 11:07:53

Core News & Articles
9 Health Care Stocks Whale Activity In Tod...
06/04/2025 17:35:27

needham-reiterates-hold-on-surmodicsto-hold
Needham Reiterates Hold on Surmodicsto Hold
04/30/2025 13:33:42

Needham analyst Mike Matson reiterates Surmodics (NASDAQ:SRDX) from Hold to Hold.

surmodics-sees-fy2025-gaap-eps-160-140-vs-061-est
Surmodics Sees FY2025 GAAP EPS $(1.60)-$(1...
04/30/2025 11:03:55

Surmodics (NASDAQ:SRDX) is looking for FY2025 GAAP EPS of $(1.60)-$(1.40) vs $(0.61) analyst estimate..

surmodics-sees-fy2025-adj-eps-062-042-vs-037-est-sees-sales-114000m-117000m-vs-12727m-est
Surmodics Sees FY2025 Adj EPS $(0.62)-$(0....
04/30/2025 11:03:45

Surmodics (NASDAQ:SRDX) is looking for FY2025 Adj EPS of $(0.62)-$(0.42) vs $(0.37) analyst estimate. sees sales of $114.000 mi...

surmodics-q2-adj-eps-013-misses-011-estimate-sales-2809m-miss-3223m-estimate
Surmodics Q2 Adj. EPS $(0.13) Misses $(0.1...
04/30/2025 11:01:09

Surmodics (NASDAQ:SRDX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) b...

Core News & Articles
Earnings Scheduled For April 30, 2025
04/30/2025 08:32:41

a-look-at-surmodicss-upcoming-earnings-report
A Look at Surmodics's Upcoming Earnings Re...
04/29/2025 19:03:00

surmodics-reveals-publication-of-transcend-trial-highlighting-drug-delivery-technology-of-its-surveil-drug-coated-balloon
Surmodics Reveals Publication Of TRANSCEND...
04/22/2025 11:05:11

deal-dispatch-us-ma-is-quiet-but-abroad-volume-is-spiking
Deal Dispatch: US M&A Is Quiet, But Abroad...
04/04/2025 19:07:59

BofA predicted a friendlier FTC under Trump. They were wrong. Deal activity was virtually flat in Q1. But it's a U.S. problem.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION